References
- Isaacs A, Lindenmann J. Virus interference. I. the interferon. Proc R Soc Lond B Biol Sci. 1957;147:258–267.
- Isaacs A, Lindenmann J, Valentine R. Virus interference. II. Some properties of interferon. Proc R Soc Lond B Biol Sci. 1957;147:268–273.
- John J, McKendry R, Pellegrini S, et al. Isolation and characterization of a new mutant human cell line unresponsive to alpha and beta interferons. Mol Cell Biol. 1991;11(8):4189–4195. DOI:https://doi.org/10.1128/mcb.11.8.4189-4195.1991.
- Velazquez L, Fellous M, Stark G, et al. A protein tyrosine kinase in the interferon alpha/beta signaling pathway. Cell. 1992;70(2):313–322. DOI:https://doi.org/10.1016/0092-8674(92)90105-L.
- Firmbach-Kraft I, Byers M, Shows T, et al. tyk2, prototype of a novel class of non-receptor tyrosine kinase genes. Oncogene. 1990;5(9):1329–1336.
- Wilks A, Harpur A, Kurban R, et al. Two novel protein-tyrosine kinases, each with a second phosphotransferase-related catalytic domain, define a new class of protein kinase. Mol Cell Biol. 1991;11(4):2057–2065. DOI:https://doi.org/10.1128/mcb.11.4.2057-2065.1991.
- Muller M, Briscoe J, Laxton C, et al. The protein tyrosine kinase JAK1 complements defects in interferon-alpha/beta and -gamma signal transduction. Nature. 1993;366(6451):129–135. DOI:https://doi.org/10.1038/366129a0.
- Johnston J, Kawamura M, Kirken R, et al. Phosphorylation and activation of the Jak-3 Janus kinase in response to interleukin-2. Nature. 1994;370(6485):151–153. DOI:https://doi.org/10.1038/370151a0.
- Liu C, Kieltyka J, Fleischmann R, et al. A decade of jakinibs: what have we learned and what may be the future. Arthritis Rheumatol. 2021;73(12):2166–2178. https://doi.org/10.1002/art.41906.
- Kremer J, Li Z, Hall S, et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Intern Med. 2013;159(4):253–261. DOI:https://doi.org/10.7326/0003-4819-159-4-201308200-00006.
- van der Heijde D, Tanaka Y, Fleischmann R, et al. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four–month phase III randomized radiographic study. Arthritis. Rheum. 2013;65(3):559–570. DOI:https://doi.org/10.1002/art.37816
- Dougados M, van der Heijde D, Chen Y, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017;76(1):88–95. DOI:https://doi.org/10.1136/annrheumdis-2016-210094.
- Burmester G, Kremer J, Van den Bosch F, et al. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2018;391(10139):2503–2512. DOI:https://doi.org/10.1016/S0140-6736(18)31115-2.
- Tanaka Y, Takeuchi T, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to conventional DMARDs: a randomised, double-blind, placebo-controlled phase III trial (RAJ3). Ann Rheum Dis. 2019;78(10):1320–1332. DOI:https://doi.org/10.1136/annrheumdis-2019-215163.
- Takeuchi T, Tanaka Y, Tanaka S, et al. Efficacy and safety of peficitinib (ASP015K) in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III randomised, double-blind, placebo-controlled trial (RAJ4) in Japan. Ann Rheum Dis. 2019;78(10):1305–1319. DOI:https://doi.org/10.1136/annrheumdis-2019-215164.
- Burmester G, Blanco R, Charles-Schoeman C, et al. Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet. 2013;381(9865):451–460. DOI:https://doi.org/10.1016/S0140-6736(12)61424-X.
- Genovese M, Kremer J, Zamani O, et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med. 2016;374(13):1243–1252. DOI:https://doi.org/10.1056/NEJMoa1507247.
- Genovese M, Fleischmann R, Combe B, et al. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet. 2018;391(10139):2513–2524. DOI:https://doi.org/10.1016/S0140-6736(18)31116-4.
- Genovese M, Kalunian K, Gottenberg J, et al. Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial. JAMA. 2019;322(4):315–325. DOI:https://doi.org/10.1001/jama.2019.9055.
- Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and Adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017;390(10093):457–468. DOI:https://doi.org/10.1016/S0140-6736(17)31618-5.
- van Vollenhoven R, Fleischmann R, Cohen S, et al. Tofacitinib or Adalimumab versus placebo in rheumatoid arthritis. N Engl J Med. 2012;367(6):508–519. DOI:https://doi.org/10.1056/NEJMoa1112072.
- Taylor P, Keystone E, van der Heijde D, et al. Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N Engl J Med. 2017;376(7):652–662. DOI:https://doi.org/10.1056/NEJMoa1608345.
- Fleischmann R, Pangan AL, In‐Ho S, et al. Upadacitinib versus placebo or Adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase 3, Double‐Blind, randomized controlled trial. Arthritis Rheumatol. 2019;71(11):1788–1800. DOI:https://doi.org/10.1002/art.41032.
- Rubbert-Roth A, Enejosa J, Pangan A, et al. Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. N Engl J Med. 2020;383(16):1511–1521. DOI:https://doi.org/10.1056/NEJMoa2008250.
- Combe B, Kivitz A, Tanaka Y, et al. Filgotinib versus placebo or Adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial . Ann Rheum Dis. 2021;80(7):848–858. DOI:https://doi.org/10.1136/annrheumdis-2020-219214.
- Fleischmann R, Kremer J, Cush J, et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med. 2012;367(6):495–507. DOI:https://doi.org/10.1056/NEJMoa1109071.
- Smolen J, Pangan A, Emery P, et al. Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study. Lancet. 2019;393(10188):2303–2311. DOI:https://doi.org/10.1016/S0140-6736(19)30419-2.
- Li Z, Hu J, Bao C, et al. Baricitinib in patients with rheumatoid arthritis with inadequate response to methotrexate: results from a phase 3 study. Clin Exp Rheumatol. 2020;38(4):732–741.
- Lee E, Fleischmann R, Hall S, et al. Tofacitinib versus Methotrexate in Rheumatoid Arthritis. N Engl J Med. 2014;370(25):2377–2386. DOI:https://doi.org/10.1056/NEJMoa1310476.
- Fleischmann R, Schiff M, van der Heijde D, et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease modifying antirheumatic drug treatment. Arthritis Rheumatol. 2017;69(3):506–517. DOI:https://doi.org/10.1002/art.39953.
- van Vollenhoven R, Takeuchi T, Pangan A, et al. Efficacy and safety of upadacitinib monotherapy in methotrexate-naive patients with moderately-to-severely active rheumatoid arthritis (SELECT-EARLY): a multicenter, multi-country, randomized, double-blind, active comparator-controlled trial. Arthritis Rheumatol. 2020;72(10):1607–1620. DOI:https://doi.org/10.1002/art.41384.
- Westhovens R, Rigby W, van der Heijde D, et al. Filgotinib in combination with methotrexate or as monotherapy versus methotrexate monotherapy in patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: the phase 3, randomised controlled FINCH 3 trial. Ann Rheum Dis. 2021;80(6):727–738. DOI:https://doi.org/10.1136/annrheumdis-2020-219213.
- Vincenti F, Tedesco-Silva H, Busque S, et al. Randomized Phase 2b Trial of Tofacitinib (CP-690,550) in De Novo Kidney Transplant Patients: efficacy, Renal Function and Safety at 1 Year. Am J Transplant. 2012;12(9):2446–2456. DOI:https://doi.org/10.1111/j.1600-6143.2012.04127.x.
- Kremer J, Bloom B, Breedveld F, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum. 2009;60(7):1895–1905. DOI:https://doi.org/10.1002/art.24567.
- Cohen S, Tanaka Y, Mariette X, et al. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020;6(3):e001395*. Integrated safety profile of tofacitinib. DOI:https://doi.org/10.1136/rmdopen-2020-001395.
- Taylor P, Takeuchi T, Burmester G, et al. Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database. Ann Rheum Dis. Epub ahead of print:. [assessed November 24, 2021]:annrheumdis-2021-221276. DOI: https://doi.org/10.1136/annrheumdis-2021-221276.
- Cohen S, van Vollenhoven R, Winthrop K, et al. Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical price. Ann Rheum Dis. 2021;80(3):304–311. https://doi.org/10.1136/annrheumdis-2020-218510. .
- Winthrop K, Tanaka Y, Takeuchi T, et al. Integrated safety analysis of filgotinib in patients with moderately to severely active rheumatoid arthritis receiving treatment over a median of 1.6 years . Ann Rheum Dis. Epub ahead of print. Assessed November 24, 2021. DOI:https://doi.org/10.1136/annrheumdis-2021-221051.
- Takeuchi T, Tanaka Y, Rokuda M, et al. A pooled safety analysis of peficitinib (ASP015K) in Asian patients with rheumatoid arthritis treated over a median of 2 years. Mod Rheumatol. 2021;31(3):543–555. DOI:https://doi.org/10.1080/14397595.2020.1836789.
- Wollenhaupt J, Lee E, Curtis J, et al. Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study. Arthritis Res Ther. 2019;21(1):89. DOI:https://doi.org/10.1186/s13075-019-1866-2.
- Charles-Schoeman C, Fleischmann R, Davignon J, et al. Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinib. Arthritis Rheumatol. 2015;67(3):616–625. https://doi.org/10.1002/art.38974. .
- Isaacs J, Zuckerman A, Krishnaswami S, et al. Changes in serum creatinine in patients with active rheumatoid arthritis treated with tofacitinib: results from clinical trials. Arthritis Res Ther. 2014;16(4):R158. DOI:https://doi.org/10.1186/ar4673.
- Queeney K, Housley W, Sokolov J, et al. Elucidating the mechanism underlying creatine phosphokinase upregulation with upadacitinib. Ann Rheum Dis. 2019;78:734–735.
- Gadina M, Le M, Schwartz D, et al. Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology. 2019;58(Supplement_1):i4–16. https://doi.org/10.1093/rheumatology/key432. .
- Doran M, Crowson C, Pond G, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. Arthritis Rheum. 2002;46(9):2287–2293. DOI:https://doi.org/10.1002/art.10524.
- Riley T, George M. Risk for infections with glucocorticoids and DMARDs in patients with rheumatoid arthritis. RMD Open. 2021;7(1):e001235.
- Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskel Dis. 2020;2:1–18.
- Aviña-Zubieta J, Choi H, Sadatsafavi M, et al. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum. 2008;59(12):1690–1697. DOI:https://doi.org/10.1002/art.24092.
- Solomon D, Karlson E, Rimm E, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107(9):1303–1307. DOI:https://doi.org/10.1161/01.CIR.0000054612.26458.B2.
- Micha R, Imamura F, von Ballmoos W, et al. Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol. 2011;108(9):1362–1370. DOI:https://doi.org/10.1016/j.amjcard.2011.06.054.
- Barnabe C, Martin B, Ghaliet W. Systematic review and meta-analysis: anti–tumor necrosis factor a therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken). 2011;63(4):522–529.
- Greenberg J, Kremer J, Curtis J, et al. Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70(4):576–582. DOI:https://doi.org/10.1136/ard.2010.129916.
- Solomon DH, Reed G, Kremer J, et al. Disease activity in rheumatoid arthritis and the risk of cardiovascular events. Arthritis Rheumatol. 2015;67(6):1449–1455. https://doi.org/10.1002/art.39098. .
- Smitten A, Simon T, Hochberg M, et al. A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis. Arthritis Res Ther. 2008;10(2):R45. https://doi.org/10.1186/ar2404. .
- Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment with increased lymphoma risk in rheumatoid arthritis. Arthritis Rheumatism. 2006;54(3):692–701. https://doi.org/10.1002/art.21675. .
- Choi H, Rho Y, Zhu Y, et al. The risk of pulmonary embolism and deep vein thrombosis in rheumatoid arthritis: a UK population-based outpatient cohort study. Ann Rheum Dis. 2013;72(7):1182–1187. DOI:https://doi.org/10.1136/annrheumdis-2012-201669.
- Lee J, Pope J. A meta-analysis of the risk of venous thromboembolism in inflammatory rheumatic diseases. Arthritis Res Ther. 2014;16(5):435.
- Molander V, Bower H, Frisel T, et al. Risk of venous thromboembolism in rheumatoid arthritis, and its association with disease activity: a nationwide cohort study from Sweden. Ann Rheum Dis. 2021;80(2):169–175. https://doi.org/10.1136/annrheumdis-2020-218419. .
- Clarke B, Yates M, Adas M, et al. The safety of JAK-1 inhibitors. Rheumatology. 2021;60(Supplement_2):ii24–30. DOI:https://doi.org/10.1093/rheumatology/keaa895.
- Mease P, Charles-Schoeman C, Cohen S, et al. Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data. Ann Rheum Dis. 2020;79(11):1400–1413. DOI:https://doi.org/10.1136/annrheumdis-2019-216761.
- Desai R, Pawar A, Khosrow-Khavar F, et al. Risk of venous thromboembolism associated with tofacitinib in patients with rheumatoid arthritis: a population-based cohort study. Rheumatology (Oxford). 2022;61(1):121–130. DOI:https://doi.org/10.1093/rheumatology/keab294.
- Khosrow-Khavar F, Kim S, Lee H, et al. Risk of cardiovascular outcomes in patients treated with tofacitinib: first results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Accessed December 4, 2021 https://acrabstracts.org/abstract/risk-of-cardiovascular-outcomes-in-patients-treated-with-tofacitinib-first-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/.
- Khosrow-Khavar F, Desai R, Lee H, et al. Risk of malignancy in patients treated with tofacitinib: results from the safety of tofacitinib in routine care patients with rheumatoid arthritis (STAR-RA) study [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Accessed December 4, 2021 https://acrabstracts.org/abstract/risk-of-malignancy-in-patients-treated-with-tofacitinib-results-from-the-safety-of-tofacitinib-in-routine-care-patients-with-rheumatoid-arthritis-star-ra-study/.
- Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology. 2019;58(Supplement_1):i34–42.
- Kremer J, BinghamIII C, Cappelli L, et al. Post-approval comparative safety study of tofacitinib and biological disease-modifying antirheumatic drugs: 5-Year results from a United States–based rheumatoid arthritis registry. ACR Open Rheumatol. 2021;3(3):173–184. https://doi.org/10.1002/acr2.11232. .
- Ytterberg S, Bhatt D, Mikuls T, et al. Safety and efficacy of tofacitinib vs TNF inhibitors in RA patients aged 50 years or older with one or more cardiovascular risks: results from a phase 3b/4 randomized safety trial [abstract]. Arthritis Rheumatol. 2021;73(suppl 10):512–519. Accessed December 4, 2021. https://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-vs-tnf-inhibitors-in-ra-patients-aged-50-years-or-older-with-one-or-more-cardiovascular-risks-results-from-a-phase-3b-4-randomized-safety-trial/.
- Charles-Schoeman C, Buch M, and Dougados M, et al. Risk factors for major adverse cardiovascular events in patients aged ≥ 50 years with RA and ≥ 1 additional cardiovascular risk factor: results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Assessed 4 December 2021. https://acrabstracts.org/abstract/risk-factors-for-major-adverse-cardiovascular-events-in-patients-aged-%e2%89%a5-50-years-with-ra-and-%e2%89%a5-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-stud/. .
- Curtis J, Yamaoka K, Chen Y, et al. Malignancies in patients aged ≥ 50 years with RA and ≥ 1 additional cardiovascular risk factor results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Accessed December 4, 2021. https://acrabstracts.org/abstract/malignancies-in-patients-aged-%e2%89%a5-50-years-with-ra-and-%e2%89%a5-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-study-of-tofacitinib-vs-tnf-inhibitors/
- Charles-Schoeman C, Fleischmann R, Mysler E, et al. The risk of venous thromboembolic events in patients with RA aged ≥ 50 years with ≥ 1 cardiovascular risk factor: results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Accessed December 4, 2021. https://acrabstracts.org/abstract/the-risk-of-venous-thromboembolic-events-in-patients-with-ra-aged-%e2%89%a5-50-years-with-%e2%89%a5-1-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-study-of-tofacitinib-vs-tn/
- Bălănescu A, Citera G, Pascual-Ramos V, et al. Incidence of infections in patients aged ≥ 50 years with RA and ≥ 1 additional cardiovascular risk factor: results from a phase 3b/4 randomized safety study of tofacitinib vs TNF inhibitors [abstract]. Arthritis Rheumatol. 2021;73(suppl 10). Accessed December 4, 2021. https://acrabstracts.org/abstract/incidence-of-infections-in-patients-aged-%e2%89%a5-50-years-with-ra-and-%e2%89%a5-1-additional-cardiovascular-risk-factor-results-from-a-phase-3b-4-randomized-safety-study-of-tofacitinib-vs-tnf-inhib/
- Ytterberg S, Bhat DE, and Mikuls T, et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. N Engl J Med. 2022;386():316–326 .
- Fleischmann R , Mysler E , Hall S. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017; 390(10093): 457–468.
- EMA product label published December 5, 2021. Assessed December 5, 2021. https://www.ema.europa.eu/en/documents/prac-recommendation/prac-recommendations-signals-adopted-7-10-june-2021-prac-meeting_en.pdf
- Upadacitinib FDA product label published December 2, 2021 Assessed 5 December 2021. https://www.rxabbvie.com/pdf/rinvoq_pi.pdf
- Tofacitinib FDA product label published December 2, 2021. http://labeling.pfizer.com/showlabeling.aspx?id=959 Assessed December 5, 2021